Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CD74 | P04233 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DDX3X | O00571 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16652302 | 0.85 | DPP4 (0.38) | L3MBTL1MIFPTGS1PTGS2POLB | |
| SCHEMBL1961906 | 0.77 | MAPT (0.40) | L3MBTL1POLBHDAC8 | |
| SCHEMBL4289951 | 0.77 | CYP19A1 (0.57) | NPC1ALDH1A1 | |
| SCHEMBL1500677 | 0.75 | MAPT (0.35) | NPC1ALDH1A1 | |
| SCHEMBL15517955 | 0.75 | P2RX7 (0.50) | NOTUML3MBTL1MAOAP2RX7MIF | |
| SCHEMBL1500672 | 0.74 | GRM1 (0.36) | NOTUM | |
| SCHEMBL1500722 | 0.74 | NOTUM (0.39) | NOTUMP2RX7NPC1DDX3X | |
| SCHEMBL5951110 | 0.74 | SMPD1 (0.33) | — | |
| SCHEMBL14481327 | 0.73 | CYP3A4 (0.42) | L3MBTL1NPC1ALDH1A1 | |
| SCHEMBL7244739 | 0.73 | GAA (0.44) | DRD2DRD4DRD3NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643023-B1 | RADIOIODINATION METHOD | GE HEALTHCARE LTD (GB) | 2018-07-18 | — | — | EP | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| US-9138493-B2 | Radioiodinated fatty acids | GE HEALTHCARE LIMITED (GB) | 2015-09-22 | — | — | US | disclosed |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-03-26 | — | — | US | disclosed |
| US-8940274-B2 | Radioiodination method | GE HEALTHCARE LIMITED (GB) | 2015-01-27 | — | — | US | disclosed |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| CN-101229164-A | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2008-07-30 | — | — | CN | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| CN-100379421-C | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2008-04-09 | — | — | CN | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| CN-1688311-A | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549313-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | NOTUM 1119/4885L3MBTL1 4616/4885MAOA 460/4885 |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | NOTUM 1184/4885L3MBTL1 4805/4885MAOA 495/4885 |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | NOTUM 1578/4885L3MBTL1 4854/4885MAOA 313/4885 |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | NOTUM 319/4885L3MBTL1 4807/4885MAOA 316/4885 |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | NOTUM 319/4885L3MBTL1 4807/4885MAOA 316/4885 |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | NOTUM 1119/4885L3MBTL1 4616/4885MAOA 460/4885 |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | NOTUM 1184/4885L3MBTL1 4805/4885MAOA 495/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | NOTUM 1184/4885L3MBTL1 4805/4885MAOA 495/4885 |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | NOTUM 1578/4885L3MBTL1 4854/4885MAOA 313/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | NOTUM 677/4885L3MBTL1 4692/4885MAOA 320/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | NOTUM 396/4885L3MBTL1 3893/4885MAOA 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.